Cargando…

Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma

A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remark...

Descripción completa

Detalles Bibliográficos
Autores principales: Horibe, Ryota, Hatakeyama, Taku, Ishikawa, Tatsuru, Sawai, Takeyuki, Hashimoto, Midori, Domen, Hiromitsu, Takakuwa, Yasunari, Satoh, Masaaki, Nishiyama, Kaoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866795/
https://www.ncbi.nlm.nih.gov/pubmed/34393158
http://dx.doi.org/10.2169/internalmedicine.6385-20
_version_ 1784655911845888000
author Horibe, Ryota
Hatakeyama, Taku
Ishikawa, Tatsuru
Sawai, Takeyuki
Hashimoto, Midori
Domen, Hiromitsu
Takakuwa, Yasunari
Satoh, Masaaki
Nishiyama, Kaoru
author_facet Horibe, Ryota
Hatakeyama, Taku
Ishikawa, Tatsuru
Sawai, Takeyuki
Hashimoto, Midori
Domen, Hiromitsu
Takakuwa, Yasunari
Satoh, Masaaki
Nishiyama, Kaoru
author_sort Horibe, Ryota
collection PubMed
description A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remarkable antitumor effects; only a single nodule remained in the right upper lobe. The nodule was diagnosed as adenocarcinoma through a biopsy. We subsequently performed right upper lobectomy for multiple primary lung cancer (MPLC). The surgical specimen contained EGFR exon 19 deletion mutations and not exon 20 insertion mutations.
format Online
Article
Text
id pubmed-8866795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-88667952022-03-14 Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma Horibe, Ryota Hatakeyama, Taku Ishikawa, Tatsuru Sawai, Takeyuki Hashimoto, Midori Domen, Hiromitsu Takakuwa, Yasunari Satoh, Masaaki Nishiyama, Kaoru Intern Med Case Report A 78-year-old woman with multiple lung nodules, epithelial growth factor receptor (EGFR) exon 20 insertion mutations, and diagnosed with advanced lung adenocarcinoma (cT4N3M1a, stage IVA), was referred to our hospital. She received immune checkpoint inhibitor (ICI) therapy. The therapy showed remarkable antitumor effects; only a single nodule remained in the right upper lobe. The nodule was diagnosed as adenocarcinoma through a biopsy. We subsequently performed right upper lobectomy for multiple primary lung cancer (MPLC). The surgical specimen contained EGFR exon 19 deletion mutations and not exon 20 insertion mutations. The Japanese Society of Internal Medicine 2021-08-13 2022-02-01 /pmc/articles/PMC8866795/ /pubmed/34393158 http://dx.doi.org/10.2169/internalmedicine.6385-20 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Horibe, Ryota
Hatakeyama, Taku
Ishikawa, Tatsuru
Sawai, Takeyuki
Hashimoto, Midori
Domen, Hiromitsu
Takakuwa, Yasunari
Satoh, Masaaki
Nishiyama, Kaoru
Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
title Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
title_full Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
title_fullStr Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
title_full_unstemmed Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
title_short Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
title_sort radical resection for second egfr-mutated primary lung cancer following immune checkpoint inhibitor monotherapy for stage iv lung adenocarcinoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866795/
https://www.ncbi.nlm.nih.gov/pubmed/34393158
http://dx.doi.org/10.2169/internalmedicine.6385-20
work_keys_str_mv AT horiberyota radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT hatakeyamataku radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT ishikawatatsuru radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT sawaitakeyuki radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT hashimotomidori radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT domenhiromitsu radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT takakuwayasunari radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT satohmasaaki radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma
AT nishiyamakaoru radicalresectionforsecondegfrmutatedprimarylungcancerfollowingimmunecheckpointinhibitormonotherapyforstageivlungadenocarcinoma